Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force
- Author:
Jin-Woo KIM
1
;
Sung-Hye KONG
;
Jae-Young KIM
;
Mi Kyung KWAK
;
Jun-Young KIM
;
Ji-Hyeon OH
;
Hyung-Youl PARK
;
BeomTaek KIM
;
Young-Kyun LEE
;
Jeong Joon HAN
;
Moon-Young KIM
;
Yong Jun CHOI
;
Yong-Dae KWON
;
Kwang-Sup SONG
;
Beom-Jun KIM
;
Sun-Jong KIM
;
Seung-Hoon BAEK
;
Dong Ock LEE
;
Han Seok CHOI
;
Ha Young KIM
;
Tae-Geon KWON
Author Information
- Publication Type:Special Article
- From:Endocrinology and Metabolism 2025;40(6):787-810
- CountryRepublic of Korea
- Language:English
- Abstract: With a rapidly aging population and increasing use of antiresorptive agents, medication-related osteonecrosis of the jaw (MRONJ) represents a growing clinical challenge worldwide. To address the need for tailored clinical guidance, a multidisciplinary task force was convened. Five Korean academic societies—the Korean Society for Bone and Mineral Research, the Korean Association of Oral and Maxillofacial Surgeons, the Korean Society of Maxillofacial Plastic and Reconstructive Surgeons, the Korean Osteoporosis Society, and the Korean Endocrine Society—collaborated to develop this position statement. The consensus was formulated through comprehensive reviews of literature, combined with three rounds of formal surveys to consolidate expert opinion on controversial topics. This position paper provides evidence-based clinical guidelines for the prevention, diagnosis, and management of MRONJ tailored to the Korean healthcare environment. The diagnostic criteria affirm the standard definition but add a provision for diagnosis based on clinical or radiographic evidence of necrotic bone, even if the traditional 8-week timeframe has not been met. The committee advocates for retaining stage 0 in the staging system to emphasize early detection and preventive intervention. Key recommendations include prescriptive, drug-specific guidelines for prophylactic drug holidays (e.g., a 2-month pause for oral bisphosphonates; timing surgery 3 to 4 months after the last denosumab injection) to minimize MRONJ risk from dental procedures. This statement also provides a clear framework for therapeutic drug holidays in established MRONJ, carefully balancing the need for jaw healing against systemic fracture risk. For treatment, this statement advocates for early and active surgical intervention across all MRONJ stages, supported by evidence of superior long-term outcomes compared to conservative management. This position statement offers a unique, evidence-based Korean clinical practice guideline for managing MRONJ. It is intended to standardize care, reduce clinical confusion, and ultimately improve patient outcomes by providing a clear framework for decision-making.
